门冬氨酸钾镁联合胺碘酮对慢性心力衰竭并室性心律失常患者QTc、QTd及心功能的影响  

Effects of potassium magnesium aspartate combined with amiodarone on QTc,QTd and cardiac function in patients with chronic heart failure and ventricular arrhythmia

作　　者：代丽媛 Dai Liyuan(Tianjin Fourth Central Hospital,Tianjin 300000,China)

机构地区：[1]天津市第四中心医院,天津300000

出　　处：《首都食品与医药》2025年第8期55-58,共4页Capital Food Medicine

摘　　要：目的探究门冬氨酸钾镁联合胺碘酮在慢性心力衰竭并室性心律失常(VA)患者中的应用效果。方法选择2023年6月-2024年6月天津市第四中心医院收治的100例慢性心力衰竭并VA患者,按随机数表法分为两组,每组各50例。两组均实施常规治疗,对照组在常规治疗基础上予以胺碘酮治疗,观察组在上述基础上予以门冬氨酸钾镁注射液治疗。对比两组临床疗效、QT间期(QTc)、QT离散度(QTd)、心功能、炎性因子及不良反应。结果观察组治疗总有效率高于对照组,有统计学差异(P<0.05);治疗后,观察组QTc、QTd、左心室收缩末容积(LVESV)、左心室舒张末容积(LVEDV)均低于对照组,左室射血分数(LVEF)较对照组高,有统计学差异(P<0.05);治疗后,观察组白介素(IL)-6、IL-1β、肿瘤坏死因子-α(TNF-α)水平低于对照组,有统计学差异(P<0.05);两组不良反应发生率对比,无统计学差异(P>0.05)。结论门冬氨酸钾镁联合胺碘酮治疗慢性心力衰竭并VA患者的疗效确切,能够减轻炎症反应,缩短QTc及QTd,改善心功能,安全性较高。Objective To explore the application effect of potassium magnesium aspartate combined with amiodarone in patients with chronic heart failure and ventricular arrhythmia(VA).Methods 100 patients with chronic heart failure and VA admitted to Tianjin Fourth Central Hospital from June 2023 to June 2024 were selected and randomly divided into two groups,with 50 patients in each group,using a random number table method.Both groups received routine treatment,with the control group receiving amiodarone on top of routine treatment,and the observation group receiving potassium magnesium aspartate injection on top of routine treatment.Compare the clinical efficacy,QT interval(QTc),QT dispersion(QTd),cardiac function,inflammatory factors,and adverse reactions between two groups.Results The total effective rate of the observation group was higher than that of the control group,with statistical differences(P<0.05);after treatment,the QTc,QTd,the left ventricular end systolic volume(LVESV)and left ventricular end diastolic volume(LVEDV)of the observation group were both lower than those in the control group,and the left ventricular ejection fraction(LVEF)was higher than that in the control group,with statistical differences(P<0.05);after treatment,the levels of interleukin-6(IL-6),IL-1β,and tumor necrosis factor alpha(TNF-α)in the observation group were lower than those in the control group,with statistical differences(P<0.05);there was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of potassium magnesium aspartate and amiodarone is effective in treating patients with chronic heart failure and VA,reducing inflammation,shortening QTc and QTd,improving cardiac function,and is safe and reliable.

关 键 词：慢性心力衰竭 室性心律失常 胺碘酮 门冬氨酸钾镁 

分 类 号：R541.6[医药卫生—心血管疾病]